The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab
Open accessAbstract
OBJECTIVE: SSc is an autoimmune disease characterized by fibrosis of the skin and internal organs. Although the aetiology remains uncertain, many reports have suggested that IL-6 is involved in SSc pathogenesis. Tocilizumab, an anti-IL-6 receptor antibody, is an anti-arthritis medicine that works through the blockade of IL-6 functions. To examine the effect of tocilizumab on SSc, we administered tocilizumab to two SSc patients. METHODS: Two dcSSc patients were administered tocilizumab at 8 mg/kg once a month for 6 months. One patient had pulmonary fibrosis assessed by CT and spirometry, and the other had chronic renal failure caused by scleroderma renal crisis. Their skin condition was monitored with a Vesmeter and the modified Rodnan total skin score (mRTSS). Skin biopsies were obtained before and after the tocilizumab treatment to investigate the histological changes. RESULTS: After tocilizumab treatment, both patients showed softening of the skin with reductions of 50.7 and 55.7% in the total z-score of Vesmeter hardness and 51.9 and 23.0% in the mRTSS, respectively. Histological examination showed thinning of the collagen fibre bundles in the dermis. The creatinine clearance in the patient with chronic renal failure improved from 38 to 55 ml/min. However, the fibrotic changes in the lung in the other patient remained unchanged. CONCLUSIONS: In the two cases of SSc that we report here, softening of the skin was observed during the treatment with tocilizumab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis
Kissin, E. Y., Merkel, P. A., & Lafyatis, R. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22186 · Cited by 123
Cited by
Khanna, D., Denton, C. P., Jahreis, A., van Laar, J. M., Frech, T. M., Anderson, M. E., Baron, M., Chung, L., Fierlbeck, G., Lakshminarayanan, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00232-4 · Cited by 683
Translating IL-6 biology into effective treatments
Choy, E. H., De Benedetti, F., Takeuchi, T., Hashizume, M., John, M. R., & Kishimoto, T. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0419-z · Cited by 668
Self-citationTargeting interleukin-6 in inflammatory autoimmune diseases and cancers
Yao, X., Huang, J., Zhong, H., Shen, N., Faggioni, R., Fung, M., & Yao, Y. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.09.004 · Cited by 664
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
Khanna, D., Lin, C. J. F., Furst, D. E., Goldin, J., Kim, G., Kuwana, M., Allanore, Y., Matucci-Cerinic, M., Distler, O., Shima, Y., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30318-0 · Cited by 662
Self-citationInterleukin (IL-6) Immunotherapy
Tanaka, T., Narazaki, M., & Kishimoto, T. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028456 · Cited by 407
Self-citation
Metadata
- Authors
- Shima, Y., Kuwahara, Y., Murota, H., Kitaba, S., Kawai, M., Hirano, T., Arimitsu, J., Narazaki, M., Hagihara, K., Ogata, A., Katayama, I., Kawase, I., Kishimoto, T., & Tanaka, T.
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-09-05
- Volume
- 49
- Issue
- 12
- Pages
- 2408-2412
- ISSN
- 1462-0324 (ISSN-L)
- 1462-0332
- OpenAlex
- W2098914621
- Cited by
- 195
- References
- 1
- FWCI
- 11.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. https://app.cochat.ai/papers/10.1093/rheumatology/keq275
- The paper
- Shima, Y., Kuwahara, Y., Murota, H., Kitaba, S., Kawai, M., Hirano, T., Arimitsu, J., Narazaki, M., Hagihara, K., Ogata, A., Katayama, I., Kawase, I., Kishimoto, T., & Tanaka, T. (2010). The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology. https://doi.org/10.1093/rheumatology/keq275
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.